Biochem/physiol Actions

Reversible: no

Primary TargetCOX-2

Product does not compete with ATP.

Target IC₅₀: 4.7 µM, 36.6 µM against the inducible isoform of COX-2 relative to COX-1, respectively

Cell permeable: yes

General description

A cell-permeable, non-steroidal, anti-inflammatory drug (NSAID) of the oxicam family that preferentially inhibits the inducible isoform of cyclooxygenase-2 (COX-2; IC₅₀ = 4.7 µM) relative to cyclooxygenase-1 (COX-1; IC₅₀ = 36.6 µM). Also inhibits the growth of colorectal cancer cells in vitro.

A cell-permeable, non-steroidal anti-inflammatory drug (NSAID) of the oxicam family which preferentially inhibits the inducible isoform of COX-2 (IC₅₀ = 4.7 µM) relative to COX-1 (IC₅₀ = 36.6 µM). Also inhibits the growth of colorectal cancer cells in vitro.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Blanco, F.J., et al. 1999. J. Rheumatol. 26, 1366.Davies, N.M., and Skjodt, N.M. 1999. Clin. Pharmacokinet. 36, 115.Goldman, A.P., et al. 1998. Carcinogenesis 19, 2195.

Packaging

Packaged under inert gas

100 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)